REGENXBIO (NASDAQ:RGNX) Insider Steve Pakola Sells 2,161 Shares

REGENXBIO Inc. (NASDAQ:RGNX) insider Steve Pakola sold 2,161 shares of REGENXBIO stock in a transaction on Thursday, July 2nd. The shares were sold at an average price of $13.64, for a total value of $29,476.04. Following the sale, the insider directly owned 213,009 shares of the company’s stock, valued at approximately $2,905,442.76. The trade was a 1.00% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Steve Pakola also recently made the following trade(s):

• On Monday, June 29th, Steve Pakola sold 19,608 shares of REGENXBIO stock. The shares were sold at an average price of $11.04, for a total value of $216,472.32.
• On Wednesday, July 1st, Steve Pakola sold 36,725 shares of REGENXBIO stock. The stock was sold at an average price of $12.86, for a total value of $472,283.50.
• On Monday, May 11th, Steve Pakola sold 15,309 shares of REGENXBIO stock. The stock was sold at an average price of $11.02, for a total value of $168,705.18.

REGENXBIO Price Performance

Shares of REGENXBIO stock opened at $14.19 on Tuesday. The firm has a market cap of $733.47 million, a price-to-earnings ratio of -2.55 and a beta of 0.90. REGENXBIO Inc. has a 52-week low of $5.45 and a 52-week high of $16.19. The stock has a 50-day simple moving average of $8.40 and a 200-day simple moving average of $9.91.

REGENXBIO (NASDAQ:RGNX) last released its quarterly earnings data on Thursday, May 14th. The biotechnology company reported ($1.72) EPS for the quarter, missing analysts’ consensus estimates of ($1.36) by ($0.36). The firm had revenue of $6.39 million during the quarter, compared to analyst estimates of $25.84 million. REGENXBIO had a negative return on equity of 232.50% and a negative net margin of 330.23%. As a group, equities research analysts predict that REGENXBIO Inc. will post -3.69 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on the stock. Bank of America reduced their price objective on shares of REGENXBIO from $25.00 to $14.00 and set a “buy” rating for the company in a research note on Friday, May 15th. Weiss Ratings restated a “sell (e+)” rating on shares of REGENXBIO in a report on Monday, June 8th. Robert W. Baird boosted their price target on REGENXBIO from $27.00 to $32.00 and gave the stock an “outperform” rating in a research report on Monday, June 22nd. Morgan Stanley set a $16.00 price target on REGENXBIO in a research note on Friday, May 15th. Finally, Barclays lowered their price objective on REGENXBIO from $37.00 to $12.00 and set an “overweight” rating on the stock in a report on Friday, May 15th. Ten research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $23.82.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. AQR Capital Management LLC lifted its position in REGENXBIO by 2,247.7% during the 1st quarter. AQR Capital Management LLC now owns 620,595 shares of the biotechnology company’s stock worth $4,437,000 after acquiring an additional 594,161 shares during the last quarter. Jane Street Group LLC lifted its position in shares of REGENXBIO by 151.1% during the 1st quarter. Jane Street Group LLC now owns 414,067 shares of the biotechnology company’s stock worth $2,961,000 after purchasing an additional 249,156 shares during the last quarter. Franklin Resources Inc. acquired a new position in shares of REGENXBIO during the 2nd quarter worth about $239,000. American Century Companies Inc. boosted its stake in REGENXBIO by 8.4% during the 2nd quarter. American Century Companies Inc. now owns 110,066 shares of the biotechnology company’s stock valued at $904,000 after purchasing an additional 8,487 shares during the period. Finally, Prudential Financial Inc. bought a new stake in REGENXBIO during the 2nd quarter valued at approximately $87,000. 88.08% of the stock is currently owned by institutional investors and hedge funds.

REGENXBIO Company Profile

REGENXBIO Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies using its proprietary NAV® AAV (adeno‐associated virus) platform. The company engineers next‐generation AAV vectors designed to deliver functional genes to targeted cells, aiming to address a range of rare genetic diseases and ocular, metabolic and neurologic disorders. REGENXBIO’s pipeline features several product candidates in various stages of preclinical and clinical development, including RGX-314 for wet age‐related macular degeneration, RGX-121 for mucopolysaccharidosis II (Hunter syndrome) and RGX-121 for other rare lysosomal storage diseases.

In addition to its internally funded programs, REGENXBIO has established partnerships with major biopharmaceutical companies to advance its NAV technology.